News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

• Solid financial situation and strong visibility:

– Cash position of €10 million

– Operations funded until Q2-2023

• Swissmedic approval for new Phase II study starting summer 2022 evaluating temelimab in patients with severe neuropsychiatric post-COVID syndromes

GENEVA–(BUSINESS WIRE)– Regulatory News:

GeNeuro (Euronext Paris: CH0308403085 – GNRO) (Paris: GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), today reported on its 2022 second quarter cash position and issued a business update.

2022 Second-quarter financial information

At June 30, 2022, GeNeuro had €10 million in cash, which include the net proceeds from the May 2022 capital increase and an unsecured €1 million bank loan that was put in place

• January 6 committee aids said Wednesday they haven’t ruled out the possibility of more public hearings.
• Thursday’s primetime hearing will be the eighth session held to investigate the Capitol attack.
• “We have far more information than we could ever present to the American people,” a committee aide said.

As the House Select Committee investigating the January 6, 2021, attack on the Capitol nears its next big public hearing on Thursday, panel staffers are suggesting they might not be done just yet.

Thanks to an influx of evidence, committee aids said on Wednesday that more hearings are not “off the table” as they have “far more information than we could ever present to the American people.”

Thursday’s primetime hearing will detail the 187 minutes in former President Donald Trump’s day when he was out of the public eye in the White House. It comes following seven previous

Congratulations! Your startup is developing a revolutionary product or service that has the potential to transform an industry. Whatever the nature of that new product or service, at its core is an innovation – perhaps an algorithm, a concept, a formula or a compilation of data – that represents a major investment of effort and resources on your part. Now you get to showcase your innovation to prospective investors and other third parties in order to bring your startup to the next level.

But there’s a catch. How can you let others in on your big, exciting innovation without compromising it? And how can you protect your innovation without breaking the bank?

In this two-post series, we first outline how trade secret law protects valuable business information such as the innovation discussed above. In the second post, we offer a primary on identifying and maintaining trade secrets, cognizant of a